Fulcrum Therapeutics Inc.

FULC | NASDAQ

Price Alert Chart Builder DCF Calculator

$3.80

+$0.04 (+1.06%)

At close: Sep 21, 2026, 4:00 PM ET

$3.80

$0 (0.00%)

After-hours: Sep 21, 2026, 7:56 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.06%

(1D)

Rating

Updated: Sep 5, 2026

23.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $289.93M

1D Range

3.76 3.80

52W Range

2.83 15.74

Valuation (TTM)

PE -3.14

PB 0.93

EV/EBITDA 0.27

Valuation (NTM)

Forward PE N/A

Forward PEG 0.04

Price Target $3.60

Cash Flow

FCF Yield -22.8%

SBC Adj. FCF Yield -27.5%

SBC Impact -20.5%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -150.0% | -16.1%

Dil EPS 3Y | 5Y -46.4% | 23.3%

FCF 3Y | 5Y -55.8% | 13.3%

Returns

ROA -26.2%

ROE -28.5%

ROIC -27.4%

Financial Health

Net Cash

$313.56M

Current Ratio 31.35

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with...

Sector Healthcare

Industry Biotechnology

Employees 9

IPO Date Jul 17, 2019

Website www.fulcrumtx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

Upside

+5.26%

Buy (1)

Hold (5)

Sell (3)

Analyst Details ➞